Cover Image
市場調查報告書

特發性肺纖維化的全球市場:2016∼2020年

Global Idiopathic Pulmonary Fibrosis 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357738
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
特發性肺纖維化的全球市場:2016∼2020年 Global Idiopathic Pulmonary Fibrosis 2016-2020
出版日期: 2016年05月05日 內容資訊: 英文 60 Pages
簡介

特發性肺纖維化是以間質性肺病知名的肺部疾病之一,廣發於50∼70歲年齡層。診斷使用的是高解析度CT,但無法根治。全球特發性肺纖維化市場在2016∼2020年這段期間預測將以年複合成長率23.97%擴大。

本報告提供全球特發性肺纖維化市場現狀與到2020年前的成長預測,彙整市場趨勢與課題,各地區趨勢,主要供應商簡介等資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 對疾病的認識
  • 病因
  • 症狀
  • 診斷
  • 管理
  • 流行病學

第6章 開發平台分析

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各給藥途徑市場區隔

  • 口服
  • 非口服

第9章 各類藥物市場區隔

  • 全身性皮質類固醇
  • 免疫抑制劑
  • 蛋白酪氨酸激酶抑制劑
  • 抗線維劑

第10章 各地區市場市場區隔

  • 各地區市場區隔
  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第11章 推動市場的要素

  • 針對開發平台候補之法律規章的特別指定
  • 患者的增加
  • 醫療未滿足需求

第12章 促進要素的影響

第13章 市場課題

  • 病因不明
  • 缺乏恰當的診斷
  • 核准以外的替代療法的使用擴大

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • Baxter International
  • Boehringer Ingelheim
  • F Hoffmann-La Roche
  • Prometheus Laboratories
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR8081

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

Technavio's analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Baxter International
  • Boehringer Ingelheim
  • F.Hoffmann-La Roche
  • Prometheus Laboratories

Other Prominent Vendors

  • Afferent Pharmaceuticals
  • Amgen
  • Biogen
  • Bristol-Myers Squibb
  • Cipla
  • FibroGen
  • Gilead Sciences
  • GlaxoSmithKline
  • GNI Group
  • Horizon Pharma
  • ImmuneWorks
  • MediciNova
  • MedImmune (subsidiary of AstraZeneca)
  • Novartis
  • Pfizer
  • Promedior
  • ProMetic Life Sciences
  • Sanofi
  • Shionogi
  • Zai Lab

Market driver

  • Unmet medical need
  • For a full, detailed list, view our report

Market challenge

  • Lack of proper diagnosis
  • For a full, detailed list, view our report

Market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Pathogenesis
  • Signs and symptoms
  • Diagnosis
  • Management
  • Epidemiology

PART 06: Pipeline analysis

  • Lebrikizumab
  • Tipelukast
  • Tralokinumab
  • FG-3019
  • Simtuzumab
  • BMS-986020
  • AF-219
  • SAR156597
  • BG00011
  • PRM-151
  • PBI-4050

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by ROA

  • Oral
  • Parenteral

PART 09: Market segmentation by drug class

  • Systemic corticosteroids
  • Immunosuppressants
  • Tyrosine kinase inhibitors
  • Anti-fibrotic agents

PART 10: Geographical segmentation

  • Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020
  • Idiopathic pulmonary fibrosis market in Americas
  • Idiopathic pulmonary fibrosis market in EMEA
  • Idiopathic pulmonary fibrosis market in APAC

PART 11: Market drivers

  • Special regulatory designations for pipeline candidates
  • Growth in patient population
  • Unmet medical needs

PART 12: Impact of drivers

PART 13: Market challenges

  • Unknown disease etiology
  • Lack of proper diagnosis
  • Increased use of off-label and alternative therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Patient assistance programs
  • Increase in M&A
  • Rise in public awareness

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Baxter International
  • Boehringer Ingelheim
  • F Hoffmann-La Roche
  • Prometheus Laboratories
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis
  • Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis
  • Exhibit 04: Treatment options for idiopathic pulmonary fibrosis
  • Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis
  • Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio
  • Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions)
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA
  • Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class
  • Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015
  • Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions)
  • Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions)
  • Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions)
  • Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions)
  • Exhibit 16: Key drivers
  • Exhibit 17: Impact of drivers
  • Exhibit 18: Key challenges
  • Exhibit 19: Impact of drivers and challenges
  • Exhibit 20: Key trends
  • Exhibit 21: Baxter International: Business segmentation by revenue 2014
  • Exhibit 22: Baxter International: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 23: Baxter International: Geographical segmentation by revenue 2014
  • Exhibit 24: Baxter International: Key takeaways
  • Exhibit 25: Boehringer Ingelheim: Business segmentation by revenue 2014
  • Exhibit 26: Boehringer Ingelheim: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 27: Boehringer Ingelheim: Geographical segmentation by revenue 2014
  • Exhibit 28: Boehringer Ingelheim: Key takeaways
  • Exhibit 29: F Hoffmann-La Roche: Business segmentation 2014 by revenue
  • Exhibit 30: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 31: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
  • Exhibit 32: F Hoffmann-La Roche: YoY growth and revenue generated from CellCept 2011-2014 ($ millions)
  • Exhibit 33: F.Hoffmann-La Roche: Key takeaways
  • Exhibit 34: Prometheus Laboratories: Product categories
  • Exhibit 35: Prometheus Laboratories: Key takeaways
Back to Top